Publications Home The History of Synthetic Biology Designing Synthetic Biotics Pipeline Our People Leadership Board of Directors Founders and Advisors Investors + Media Company Overview News News Releases In the News Events & Presentations Events Presentations Publications Stock Information Stock Quote & Chart Analyst Coverage Corporate Governance Governance Highlights Management Team Board of Directors Committee Composition Board Diversity Matrix Financials Quarterly Results Investor Resources FAQs Contact IR Email Alerts RSS Feeds Scientific Congress Presentations | Scientific Posters | Peer-Reviewed Manuscripts Scientific Congress Presentations Synpheny-1: A Phase 2 Study of the Efficacy and Safety of SYNB1618 and SYNB1934 in Patients with Phenylketonuria, March 19, 2023 Identification and Qualification of CQAs for Live Biotherapeutic Products, May 2, 2022 Reduction in Plasma Phe Levels in Patients with PKU with SYNB1618: Interim Analysis from Ongoing Phase 2 Study, International Congress of Inborn Errors of Metabolism, November 22, 2021 Proof-of-Concept Study of Oxalate-Consuming Synthetic Biotic Medicine SYNB8802 in Enteric Hyperoxaluria after Roux-en-Y Surgery, American Society of Nephrology Kidney Week, November 5, 2021 Relationship Between 24-Hour Urinary Oxalate and Incident CKD Among Patients with and without Underlying GI Disease, American Society of Nephrology Kidney Week, November 5, 2021 Synthetic Biotic Medicines for the Treatment of PKU, Global PKU Patient Conference, September 10, 2021 Safety and Tolerability of an Oxalate-Consuming Synthetic Biotic Medicine, American Urological Association (AUA) Annual Meeting, September 10, 2021 Novel Human IL-22- Secreting Synthetic Biotic Medicine for the Treatment of Inflammatory Bowel Disease (IBD), Digestive Disease Week (DDW), May 23, 2021 Intratumoral injection of SYNB1891: A Synthetic Biotic medicine designed to activate the innate immune system, American Association for Cancer Research (AACR), April 10, 2021 In Silico Simulation to Predict Activity of a Synthetic Biotic, SYNB8802, in Healthy Volunteers and Patients with Enteric Hyperoxaluria, 3rd International Conference on Microbiome Engineering, December 9, 2020 Development of a Synthetic Biotic for the Treatment of Enteric Hyperoxaluria, 3rd International Conference on Microbiome Engineering, December 9, 2020 Development of a Synthetic Biotic, SYNB8802, for the Treatment of Enteric Hyperoxaluria, October 22, 2020 A Phase 1/2a Oral Placebo-controlled Study of SYNB1618 in Healthy Adult Volunteers and Subjects with Phenylketonuria, Society for the Study of Inborn Error of Metabolism (SSIEM) 2019, September 4, 2019 Using Synthetic Biotic Medicines to Activate Innate and Adaptive Immunity and Drive Antitumor Immune Responses, Federation of Clinical Immunology Societies (FOCIS), June 25, 2018 Therapeutic Programming of Synthetic Biotic Medicines, American Society for Microbiology, June 11, 2018 Scientific Posters Improvements of SYNB1353 , an Engineered Bacteria for the Treatment of Homocystinuria, Lead to Increased In vitro and In vivo Degradation of Methionine SYNB8802v1 Lowers Urinary Oxalate Using a Controlled Dietary Model of Hyperoxaluria in Patients with Roux-en-Y Gastric Bypass, November 4, 2023 SYNB1353, a Synthetic Biotic Engineered for the Treatment of HCU, Metabolizes Methionine and Lowers Homocysteine in Preclinical and Clinical Models, June 1, 2023 Engineering Synthetic Biotics to Secrete Therapeutic Proteins, May 31, 2023 Robust Performance and Rapid Construction of Live Bacterial Therapeutics Lacking the Colibactin Gene Cluster, May 30, 2023 Development of SYNB1934 for the Treatment of Phenylketonuria: Phase 2 Data and Phase 3 Design, April 21, 2023 SYNB1353, A Proposed Therapy for Homocystinuria, Lowers Plasma Methionine and Homocysteine in Healthy Volunteers Exposed to a Methionine Challenge, March 19, 2023 Gastrointestinal Methionine Metabolism with Live Biotherapeutic SYNB1353 Results in Improved Plasma Methionine and Homocysteine Levels in Mice and Nonhuman Primates, March 19, 2023 Synthetic Biotics As a Versatile Platform to Treat Inflammatory Bowel Disease, February 1, 2023 Methionine Restriction Prevents Cystine Urolithiasis in a Mouse Model of Cystinuria, November 4, 2022 Consumption of Uric Acid in the Gastrointestinal Tract with Engineered E. coli Nissle as a Potential Treatment for Gout, November 4, 2022 Synthetic Biotic Producing AHR Metabolites for the Treatment of Inflammatory Bowel Disease, May 21, 2022 Engineering Synthetic Biotic Medicines to Secrete Human Proteins and Short Chain Fatty Acids as a Versatile Platform to Treat Inflammatory Bowel Disease, May 21, 2022 Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria with Live Biotherapeutic SYNB1618: Interim Analysis from an Ongoing Phase 2 Study, May 13, 2022 Dietary Management Outcomes During Synpheny-1, a Phase 2 Clinical Trial of a Live Biotherapeutic, SYNB1618, for the Management of Phenylketonuria, May 5, 2022 Characterization of Dietary Protein Intake in PKU Patients, May 5, 2022 A Synthetic Biotic, SYNB8802, Lowers Urinary Oxalate in Preclinical Models and Healthy Volunteers with Induced Dietary Hyperoxaluria, May 2, 2022 Engineering E. coli Nissle 1917 to Consume Uric Acid in the GI Tract, May 2, 2022 Development of SYNB1353, A Synthetic Biotic Engineered to Consume Methionine for the Treatment of Homocystinuria, May 2, 2022 Local Delivery of Synthetic Biotics to Treat Inflammatory Bowel Disease, May 2, 2022 Biosensor-Enabled Optimization of SYNB1934, a Synthetic Biotic for Phenylketonuria Demonstrating Clinical Efficacy, May 2, 2022 Activity of SYNB1353, an Investigational Methionine-Consuming Synthetic Biotic Medicine, in an Acute Nonhuman Primate Model of Homocystinuria, April 11, 2022 Comparison of Phenylalanine Absorption in Healthy Volunteers and PKU Patients in the Synpheny-1 Study, April 11, 2022 Development of an Investigational Methionine-consuming Synthetic Biotic Medicine (SYNB1353) for the Treatment of Homocystinuria, International Congress of Inborn Errors of Metabolism, November 23, 2021 Development of an Optimized and Improved Phenylalanine Degrading Live Bacterial Therapeutic, SYNB1934, for the Treatment of Phenylketonuria, International Congress of Inborn Errors of Metabolism, November 23, 2021 Enhanced Potential for Phe Lowering with SYNB1934, a Live Biotherapeutic with an Improved PAL Variant, International Congress of Inborn Errors of Metabolism, November 23, 2021 Characterization of Dietary Protein Intake in PKU Patients, International Congress of Inborn Errors of Metabolism, November 23, 2021 SYNB1891, a bacterium engineered to produce a STING agonist, demonstrates target engagement in humans following intratumoral injection, Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 10, 2021 Synthetic Biology Approaches for the Optimization and Improvement of a Live Bacterial Therapeutic for the Treatment of Phenylketonuria (PKU), Synthetic Biology: Engineering, Evolution & Design (SEED) Conference, June 15, 2021 Development of a Synthetic Biotic, SYNB8802, for the Treatment of Enteric Hyperoxaluria, Synthetic Biology: Engineering, Evolution & Design (SEED) Conference, June 15, 2021 Randomized, Placebo-Controlled Study of Lyophilized Formulation of SYNB1618 in Healthy Adult Volunteers, American College of Medical Genetics (ACMG) Annual Meeting, April 13, 2021 Simulations to Estimate Effects of Reduced Phenylalanine Intake on Blood Phenylalanine in Phenylketonuria, Society for the Study of Inborn Errors of Metabolism, September 4, 2019 A Synthetic Live Bacterial Therapeutic Organism for the Treatment of the Human Metabolic Disease Phenylketonuria, Synthetic Biology: Engineering, Evolution & Design (SEED) Conference, June 23, 2019 Engineering Synthetic Biotic Medicines for the Treatment of Cancer, Synthetic Biology: Engineering, Evolution & Design (SEED) Conference, June 23, 2019 The development of leucine consuming strains as therapeutics for Maple Syrup Urine Disease, Synthetic Biology: Engineering, Evolution & Design (SEED) Conference, June 23, 2019 Development and Preclinical Characterization of a Solid Oral Formulation of a Synthetic Biotic for the Treatment of PKU, American Society of Gene & Cell Therapy, April 30, 2019 Activation of innate and adaptive immunity via combinatorial immunotherapy using Synthetic Biotic Medicines, American Association for Cancer Research, July 1, 2018 A Synthetic Biology Approach for the Treatment of Cancer and Inflammation, Federation of Clinical Immunology Societies, June 25, 2018 Metabolic Modulation of the Tumor Microenvironment using Synthetic Biotic Medicines, American Association for Cancer Research (AACR), April 23, 2018 Peer-Reviewed Manuscripts Phenylketonuria (PKU) Efficacy and safety of a synthetic biotic for treatment of phenylketonuria: a phase 2 clinical trial | Nature Metabolism Improvement of a synthetic live bacterial therapeutic for phenylketonuria with biosensor-enabled enzyme engineering, Adolfsen et al. Nature Communications (2021) 12:6215. Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria, Charbonneau et al. Communications Biology (2021) 4:898. Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study | Nature Metabolism Puurunen, et al. Nature Metabolism. (2021) 3:1125–1132. Characterization of an engineered live bacterial therapeutic for the treatment of phenylketonuria in a human gut-on-a-chip, Nelson et al. Nature Communications (2021) 12:2805. Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria, Isabella et al. Nature Biotechnology (2018). Immunology Lactate limits CNS autoimmunity by stabilizing HIF-1α in dendritic cells. Sanmarco, L.M. Nature (2023). Phase I study of SYNB1891, an engineered E coli Nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies, American Association for Cancer Research, May 9, 2023 Metabolic modulation of tumours with engineered bacteria for immunotherapy, Canale et al. Nature (2021) 598: 662–666. Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity, Leventhal et al. Nature Communications. (2020) 11:2739. Other Metabolic & Synthetic Biotic Platform Twenty-four-hour urine oxalate and risk of chronic kidney disease Kouno, T., Zeng, S., Wang, Y., Duan, Y., Lang, S., Gao, B. et al. (2023) Engineered bacteria producing aryl-hydrocarbon receptor agonists protect against ethanol-induced liver disease in mice. Alcohol: Clinical and Experimental Research, 00, 1–12. Robust performance of a live bacterial therapeutic chassis lacking the colibactin gene cluster, Kalantari, et al. PLOS ONE (2023) An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and in silico simulations of enteric hyperoxaluria, Lubkowicz, et al. Molecular Systems Biology (2022)18:10539 Development of Synthetic Biotics as Treatments for Human Diseases , Brennan, et al. Synthetic Biology (2022) 7(1), 1-7. Rapid cell counting and viability detection method of Escherichia coli Nissle using image cytometry, Perry et al. Journal of Microbiological Methods (2022) 192: 106381. Engineering living therapeutics with synthetic biology, Cubillos-Ruiz et al. Nature Reviews Drug Discovery (2021) 20:941–960. Developing a new class of engineered live bacterial therapeutics to treat human diseases, Charbonneau et al. Nature Communications. (2020) 11:1738. An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans, Kurtz et al. Science Translational Medicine (2019) 11:475. Translational Development of Microbiome-Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates, Kurtz et al. Clin Transl Sci (2018) 11: 200–207. Investor Resources Contact IR Investor FAQs RSS Feeds Investor Email Alerts Email
Scientific Congress Presentations | Scientific Posters | Peer-Reviewed Manuscripts Scientific Congress Presentations Synpheny-1: A Phase 2 Study of the Efficacy and Safety of SYNB1618 and SYNB1934 in Patients with Phenylketonuria, March 19, 2023 Identification and Qualification of CQAs for Live Biotherapeutic Products, May 2, 2022 Reduction in Plasma Phe Levels in Patients with PKU with SYNB1618: Interim Analysis from Ongoing Phase 2 Study, International Congress of Inborn Errors of Metabolism, November 22, 2021 Proof-of-Concept Study of Oxalate-Consuming Synthetic Biotic Medicine SYNB8802 in Enteric Hyperoxaluria after Roux-en-Y Surgery, American Society of Nephrology Kidney Week, November 5, 2021 Relationship Between 24-Hour Urinary Oxalate and Incident CKD Among Patients with and without Underlying GI Disease, American Society of Nephrology Kidney Week, November 5, 2021 Synthetic Biotic Medicines for the Treatment of PKU, Global PKU Patient Conference, September 10, 2021 Safety and Tolerability of an Oxalate-Consuming Synthetic Biotic Medicine, American Urological Association (AUA) Annual Meeting, September 10, 2021 Novel Human IL-22- Secreting Synthetic Biotic Medicine for the Treatment of Inflammatory Bowel Disease (IBD), Digestive Disease Week (DDW), May 23, 2021 Intratumoral injection of SYNB1891: A Synthetic Biotic medicine designed to activate the innate immune system, American Association for Cancer Research (AACR), April 10, 2021 In Silico Simulation to Predict Activity of a Synthetic Biotic, SYNB8802, in Healthy Volunteers and Patients with Enteric Hyperoxaluria, 3rd International Conference on Microbiome Engineering, December 9, 2020 Development of a Synthetic Biotic for the Treatment of Enteric Hyperoxaluria, 3rd International Conference on Microbiome Engineering, December 9, 2020 Development of a Synthetic Biotic, SYNB8802, for the Treatment of Enteric Hyperoxaluria, October 22, 2020 A Phase 1/2a Oral Placebo-controlled Study of SYNB1618 in Healthy Adult Volunteers and Subjects with Phenylketonuria, Society for the Study of Inborn Error of Metabolism (SSIEM) 2019, September 4, 2019 Using Synthetic Biotic Medicines to Activate Innate and Adaptive Immunity and Drive Antitumor Immune Responses, Federation of Clinical Immunology Societies (FOCIS), June 25, 2018 Therapeutic Programming of Synthetic Biotic Medicines, American Society for Microbiology, June 11, 2018 Scientific Posters Improvements of SYNB1353 , an Engineered Bacteria for the Treatment of Homocystinuria, Lead to Increased In vitro and In vivo Degradation of Methionine SYNB8802v1 Lowers Urinary Oxalate Using a Controlled Dietary Model of Hyperoxaluria in Patients with Roux-en-Y Gastric Bypass, November 4, 2023 SYNB1353, a Synthetic Biotic Engineered for the Treatment of HCU, Metabolizes Methionine and Lowers Homocysteine in Preclinical and Clinical Models, June 1, 2023 Engineering Synthetic Biotics to Secrete Therapeutic Proteins, May 31, 2023 Robust Performance and Rapid Construction of Live Bacterial Therapeutics Lacking the Colibactin Gene Cluster, May 30, 2023 Development of SYNB1934 for the Treatment of Phenylketonuria: Phase 2 Data and Phase 3 Design, April 21, 2023 SYNB1353, A Proposed Therapy for Homocystinuria, Lowers Plasma Methionine and Homocysteine in Healthy Volunteers Exposed to a Methionine Challenge, March 19, 2023 Gastrointestinal Methionine Metabolism with Live Biotherapeutic SYNB1353 Results in Improved Plasma Methionine and Homocysteine Levels in Mice and Nonhuman Primates, March 19, 2023 Synthetic Biotics As a Versatile Platform to Treat Inflammatory Bowel Disease, February 1, 2023 Methionine Restriction Prevents Cystine Urolithiasis in a Mouse Model of Cystinuria, November 4, 2022 Consumption of Uric Acid in the Gastrointestinal Tract with Engineered E. coli Nissle as a Potential Treatment for Gout, November 4, 2022 Synthetic Biotic Producing AHR Metabolites for the Treatment of Inflammatory Bowel Disease, May 21, 2022 Engineering Synthetic Biotic Medicines to Secrete Human Proteins and Short Chain Fatty Acids as a Versatile Platform to Treat Inflammatory Bowel Disease, May 21, 2022 Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria with Live Biotherapeutic SYNB1618: Interim Analysis from an Ongoing Phase 2 Study, May 13, 2022 Dietary Management Outcomes During Synpheny-1, a Phase 2 Clinical Trial of a Live Biotherapeutic, SYNB1618, for the Management of Phenylketonuria, May 5, 2022 Characterization of Dietary Protein Intake in PKU Patients, May 5, 2022 A Synthetic Biotic, SYNB8802, Lowers Urinary Oxalate in Preclinical Models and Healthy Volunteers with Induced Dietary Hyperoxaluria, May 2, 2022 Engineering E. coli Nissle 1917 to Consume Uric Acid in the GI Tract, May 2, 2022 Development of SYNB1353, A Synthetic Biotic Engineered to Consume Methionine for the Treatment of Homocystinuria, May 2, 2022 Local Delivery of Synthetic Biotics to Treat Inflammatory Bowel Disease, May 2, 2022 Biosensor-Enabled Optimization of SYNB1934, a Synthetic Biotic for Phenylketonuria Demonstrating Clinical Efficacy, May 2, 2022 Activity of SYNB1353, an Investigational Methionine-Consuming Synthetic Biotic Medicine, in an Acute Nonhuman Primate Model of Homocystinuria, April 11, 2022 Comparison of Phenylalanine Absorption in Healthy Volunteers and PKU Patients in the Synpheny-1 Study, April 11, 2022 Development of an Investigational Methionine-consuming Synthetic Biotic Medicine (SYNB1353) for the Treatment of Homocystinuria, International Congress of Inborn Errors of Metabolism, November 23, 2021 Development of an Optimized and Improved Phenylalanine Degrading Live Bacterial Therapeutic, SYNB1934, for the Treatment of Phenylketonuria, International Congress of Inborn Errors of Metabolism, November 23, 2021 Enhanced Potential for Phe Lowering with SYNB1934, a Live Biotherapeutic with an Improved PAL Variant, International Congress of Inborn Errors of Metabolism, November 23, 2021 Characterization of Dietary Protein Intake in PKU Patients, International Congress of Inborn Errors of Metabolism, November 23, 2021 SYNB1891, a bacterium engineered to produce a STING agonist, demonstrates target engagement in humans following intratumoral injection, Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 10, 2021 Synthetic Biology Approaches for the Optimization and Improvement of a Live Bacterial Therapeutic for the Treatment of Phenylketonuria (PKU), Synthetic Biology: Engineering, Evolution & Design (SEED) Conference, June 15, 2021 Development of a Synthetic Biotic, SYNB8802, for the Treatment of Enteric Hyperoxaluria, Synthetic Biology: Engineering, Evolution & Design (SEED) Conference, June 15, 2021 Randomized, Placebo-Controlled Study of Lyophilized Formulation of SYNB1618 in Healthy Adult Volunteers, American College of Medical Genetics (ACMG) Annual Meeting, April 13, 2021 Simulations to Estimate Effects of Reduced Phenylalanine Intake on Blood Phenylalanine in Phenylketonuria, Society for the Study of Inborn Errors of Metabolism, September 4, 2019 A Synthetic Live Bacterial Therapeutic Organism for the Treatment of the Human Metabolic Disease Phenylketonuria, Synthetic Biology: Engineering, Evolution & Design (SEED) Conference, June 23, 2019 Engineering Synthetic Biotic Medicines for the Treatment of Cancer, Synthetic Biology: Engineering, Evolution & Design (SEED) Conference, June 23, 2019 The development of leucine consuming strains as therapeutics for Maple Syrup Urine Disease, Synthetic Biology: Engineering, Evolution & Design (SEED) Conference, June 23, 2019 Development and Preclinical Characterization of a Solid Oral Formulation of a Synthetic Biotic for the Treatment of PKU, American Society of Gene & Cell Therapy, April 30, 2019 Activation of innate and adaptive immunity via combinatorial immunotherapy using Synthetic Biotic Medicines, American Association for Cancer Research, July 1, 2018 A Synthetic Biology Approach for the Treatment of Cancer and Inflammation, Federation of Clinical Immunology Societies, June 25, 2018 Metabolic Modulation of the Tumor Microenvironment using Synthetic Biotic Medicines, American Association for Cancer Research (AACR), April 23, 2018 Peer-Reviewed Manuscripts Phenylketonuria (PKU) Efficacy and safety of a synthetic biotic for treatment of phenylketonuria: a phase 2 clinical trial | Nature Metabolism Improvement of a synthetic live bacterial therapeutic for phenylketonuria with biosensor-enabled enzyme engineering, Adolfsen et al. Nature Communications (2021) 12:6215. Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria, Charbonneau et al. Communications Biology (2021) 4:898. Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study | Nature Metabolism Puurunen, et al. Nature Metabolism. (2021) 3:1125–1132. Characterization of an engineered live bacterial therapeutic for the treatment of phenylketonuria in a human gut-on-a-chip, Nelson et al. Nature Communications (2021) 12:2805. Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria, Isabella et al. Nature Biotechnology (2018). Immunology Lactate limits CNS autoimmunity by stabilizing HIF-1α in dendritic cells. Sanmarco, L.M. Nature (2023). Phase I study of SYNB1891, an engineered E coli Nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies, American Association for Cancer Research, May 9, 2023 Metabolic modulation of tumours with engineered bacteria for immunotherapy, Canale et al. Nature (2021) 598: 662–666. Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity, Leventhal et al. Nature Communications. (2020) 11:2739. Other Metabolic & Synthetic Biotic Platform Twenty-four-hour urine oxalate and risk of chronic kidney disease Kouno, T., Zeng, S., Wang, Y., Duan, Y., Lang, S., Gao, B. et al. (2023) Engineered bacteria producing aryl-hydrocarbon receptor agonists protect against ethanol-induced liver disease in mice. Alcohol: Clinical and Experimental Research, 00, 1–12. Robust performance of a live bacterial therapeutic chassis lacking the colibactin gene cluster, Kalantari, et al. PLOS ONE (2023) An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and in silico simulations of enteric hyperoxaluria, Lubkowicz, et al. Molecular Systems Biology (2022)18:10539 Development of Synthetic Biotics as Treatments for Human Diseases , Brennan, et al. Synthetic Biology (2022) 7(1), 1-7. Rapid cell counting and viability detection method of Escherichia coli Nissle using image cytometry, Perry et al. Journal of Microbiological Methods (2022) 192: 106381. Engineering living therapeutics with synthetic biology, Cubillos-Ruiz et al. Nature Reviews Drug Discovery (2021) 20:941–960. Developing a new class of engineered live bacterial therapeutics to treat human diseases, Charbonneau et al. Nature Communications. (2020) 11:1738. An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans, Kurtz et al. Science Translational Medicine (2019) 11:475. Translational Development of Microbiome-Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates, Kurtz et al. Clin Transl Sci (2018) 11: 200–207.
Synpheny-1: A Phase 2 Study of the Efficacy and Safety of SYNB1618 and SYNB1934 in Patients with Phenylketonuria, March 19, 2023
Reduction in Plasma Phe Levels in Patients with PKU with SYNB1618: Interim Analysis from Ongoing Phase 2 Study, International Congress of Inborn Errors of Metabolism, November 22, 2021
Proof-of-Concept Study of Oxalate-Consuming Synthetic Biotic Medicine SYNB8802 in Enteric Hyperoxaluria after Roux-en-Y Surgery, American Society of Nephrology Kidney Week, November 5, 2021
Relationship Between 24-Hour Urinary Oxalate and Incident CKD Among Patients with and without Underlying GI Disease, American Society of Nephrology Kidney Week, November 5, 2021
Synthetic Biotic Medicines for the Treatment of PKU, Global PKU Patient Conference, September 10, 2021
Safety and Tolerability of an Oxalate-Consuming Synthetic Biotic Medicine, American Urological Association (AUA) Annual Meeting, September 10, 2021
Novel Human IL-22- Secreting Synthetic Biotic Medicine for the Treatment of Inflammatory Bowel Disease (IBD), Digestive Disease Week (DDW), May 23, 2021
Intratumoral injection of SYNB1891: A Synthetic Biotic medicine designed to activate the innate immune system, American Association for Cancer Research (AACR), April 10, 2021
In Silico Simulation to Predict Activity of a Synthetic Biotic, SYNB8802, in Healthy Volunteers and Patients with Enteric Hyperoxaluria, 3rd International Conference on Microbiome Engineering, December 9, 2020
Development of a Synthetic Biotic for the Treatment of Enteric Hyperoxaluria, 3rd International Conference on Microbiome Engineering, December 9, 2020
Development of a Synthetic Biotic, SYNB8802, for the Treatment of Enteric Hyperoxaluria, October 22, 2020
A Phase 1/2a Oral Placebo-controlled Study of SYNB1618 in Healthy Adult Volunteers and Subjects with Phenylketonuria, Society for the Study of Inborn Error of Metabolism (SSIEM) 2019, September 4, 2019
Using Synthetic Biotic Medicines to Activate Innate and Adaptive Immunity and Drive Antitumor Immune Responses, Federation of Clinical Immunology Societies (FOCIS), June 25, 2018
Therapeutic Programming of Synthetic Biotic Medicines, American Society for Microbiology, June 11, 2018
Improvements of SYNB1353 , an Engineered Bacteria for the Treatment of Homocystinuria, Lead to Increased In vitro and In vivo Degradation of Methionine
SYNB8802v1 Lowers Urinary Oxalate Using a Controlled Dietary Model of Hyperoxaluria in Patients with Roux-en-Y Gastric Bypass, November 4, 2023
SYNB1353, a Synthetic Biotic Engineered for the Treatment of HCU, Metabolizes Methionine and Lowers Homocysteine in Preclinical and Clinical Models, June 1, 2023
Robust Performance and Rapid Construction of Live Bacterial Therapeutics Lacking the Colibactin Gene Cluster, May 30, 2023
Development of SYNB1934 for the Treatment of Phenylketonuria: Phase 2 Data and Phase 3 Design, April 21, 2023
SYNB1353, A Proposed Therapy for Homocystinuria, Lowers Plasma Methionine and Homocysteine in Healthy Volunteers Exposed to a Methionine Challenge, March 19, 2023
Gastrointestinal Methionine Metabolism with Live Biotherapeutic SYNB1353 Results in Improved Plasma Methionine and Homocysteine Levels in Mice and Nonhuman Primates, March 19, 2023
Methionine Restriction Prevents Cystine Urolithiasis in a Mouse Model of Cystinuria, November 4, 2022
Consumption of Uric Acid in the Gastrointestinal Tract with Engineered E. coli Nissle as a Potential Treatment for Gout, November 4, 2022
Synthetic Biotic Producing AHR Metabolites for the Treatment of Inflammatory Bowel Disease, May 21, 2022
Engineering Synthetic Biotic Medicines to Secrete Human Proteins and Short Chain Fatty Acids as a Versatile Platform to Treat Inflammatory Bowel Disease, May 21, 2022
Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria with Live Biotherapeutic SYNB1618: Interim Analysis from an Ongoing Phase 2 Study, May 13, 2022
Dietary Management Outcomes During Synpheny-1, a Phase 2 Clinical Trial of a Live Biotherapeutic, SYNB1618, for the Management of Phenylketonuria, May 5, 2022
A Synthetic Biotic, SYNB8802, Lowers Urinary Oxalate in Preclinical Models and Healthy Volunteers with Induced Dietary Hyperoxaluria, May 2, 2022
Development of SYNB1353, A Synthetic Biotic Engineered to Consume Methionine for the Treatment of Homocystinuria, May 2, 2022
Biosensor-Enabled Optimization of SYNB1934, a Synthetic Biotic for Phenylketonuria Demonstrating Clinical Efficacy, May 2, 2022
Activity of SYNB1353, an Investigational Methionine-Consuming Synthetic Biotic Medicine, in an Acute Nonhuman Primate Model of Homocystinuria, April 11, 2022
Comparison of Phenylalanine Absorption in Healthy Volunteers and PKU Patients in the Synpheny-1 Study, April 11, 2022
Development of an Investigational Methionine-consuming Synthetic Biotic Medicine (SYNB1353) for the Treatment of Homocystinuria, International Congress of Inborn Errors of Metabolism, November 23, 2021
Development of an Optimized and Improved Phenylalanine Degrading Live Bacterial Therapeutic, SYNB1934, for the Treatment of Phenylketonuria, International Congress of Inborn Errors of Metabolism, November 23, 2021
Enhanced Potential for Phe Lowering with SYNB1934, a Live Biotherapeutic with an Improved PAL Variant, International Congress of Inborn Errors of Metabolism, November 23, 2021
Characterization of Dietary Protein Intake in PKU Patients, International Congress of Inborn Errors of Metabolism, November 23, 2021
SYNB1891, a bacterium engineered to produce a STING agonist, demonstrates target engagement in humans following intratumoral injection, Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 10, 2021
Synthetic Biology Approaches for the Optimization and Improvement of a Live Bacterial Therapeutic for the Treatment of Phenylketonuria (PKU), Synthetic Biology: Engineering, Evolution & Design (SEED) Conference, June 15, 2021
Development of a Synthetic Biotic, SYNB8802, for the Treatment of Enteric Hyperoxaluria, Synthetic Biology: Engineering, Evolution & Design (SEED) Conference, June 15, 2021
Randomized, Placebo-Controlled Study of Lyophilized Formulation of SYNB1618 in Healthy Adult Volunteers, American College of Medical Genetics (ACMG) Annual Meeting, April 13, 2021
Simulations to Estimate Effects of Reduced Phenylalanine Intake on Blood Phenylalanine in Phenylketonuria, Society for the Study of Inborn Errors of Metabolism, September 4, 2019
A Synthetic Live Bacterial Therapeutic Organism for the Treatment of the Human Metabolic Disease Phenylketonuria, Synthetic Biology: Engineering, Evolution & Design (SEED) Conference, June 23, 2019
Engineering Synthetic Biotic Medicines for the Treatment of Cancer, Synthetic Biology: Engineering, Evolution & Design (SEED) Conference, June 23, 2019
The development of leucine consuming strains as therapeutics for Maple Syrup Urine Disease, Synthetic Biology: Engineering, Evolution & Design (SEED) Conference, June 23, 2019
Development and Preclinical Characterization of a Solid Oral Formulation of a Synthetic Biotic for the Treatment of PKU, American Society of Gene & Cell Therapy, April 30, 2019
Activation of innate and adaptive immunity via combinatorial immunotherapy using Synthetic Biotic Medicines, American Association for Cancer Research, July 1, 2018
A Synthetic Biology Approach for the Treatment of Cancer and Inflammation, Federation of Clinical Immunology Societies, June 25, 2018
Metabolic Modulation of the Tumor Microenvironment using Synthetic Biotic Medicines, American Association for Cancer Research (AACR), April 23, 2018
Efficacy and safety of a synthetic biotic for treatment of phenylketonuria: a phase 2 clinical trial | Nature Metabolism
Improvement of a synthetic live bacterial therapeutic for phenylketonuria with biosensor-enabled enzyme engineering, Adolfsen et al. Nature Communications (2021) 12:6215.
Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria, Charbonneau et al. Communications Biology (2021) 4:898.
Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study | Nature Metabolism Puurunen, et al. Nature Metabolism. (2021) 3:1125–1132.
Characterization of an engineered live bacterial therapeutic for the treatment of phenylketonuria in a human gut-on-a-chip, Nelson et al. Nature Communications (2021) 12:2805.
Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria, Isabella et al. Nature Biotechnology (2018).
Lactate limits CNS autoimmunity by stabilizing HIF-1α in dendritic cells. Sanmarco, L.M. Nature (2023).
Phase I study of SYNB1891, an engineered E coli Nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies, American Association for Cancer Research, May 9, 2023
Metabolic modulation of tumours with engineered bacteria for immunotherapy, Canale et al. Nature (2021) 598: 662–666.
Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity, Leventhal et al. Nature Communications. (2020) 11:2739.
Kouno, T., Zeng, S., Wang, Y., Duan, Y., Lang, S., Gao, B. et al. (2023) Engineered bacteria producing aryl-hydrocarbon receptor agonists protect against ethanol-induced liver disease in mice. Alcohol: Clinical and Experimental Research, 00, 1–12.
Robust performance of a live bacterial therapeutic chassis lacking the colibactin gene cluster, Kalantari, et al. PLOS ONE (2023)
An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and in silico simulations of enteric hyperoxaluria, Lubkowicz, et al. Molecular Systems Biology (2022)18:10539
Development of Synthetic Biotics as Treatments for Human Diseases , Brennan, et al. Synthetic Biology (2022) 7(1), 1-7.
Rapid cell counting and viability detection method of Escherichia coli Nissle using image cytometry, Perry et al. Journal of Microbiological Methods (2022) 192: 106381.
Engineering living therapeutics with synthetic biology, Cubillos-Ruiz et al. Nature Reviews Drug Discovery (2021) 20:941–960.
Developing a new class of engineered live bacterial therapeutics to treat human diseases, Charbonneau et al. Nature Communications. (2020) 11:1738.
An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans, Kurtz et al. Science Translational Medicine (2019) 11:475.
Translational Development of Microbiome-Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates, Kurtz et al. Clin Transl Sci (2018) 11: 200–207.